利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

150 条记录 (耗时 0.037 秒)

    RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA (MVA) RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE
    91.
    发明授权
    RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA (MVA) RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE 有权

    公开(公告)号：EP2879702B1

    公开(公告)日：2019-11-27

    申请号：EP13717721.8

    申请日：2013-03-15

    申请人： Bavarian Nordic A/S

    发明人： CHEMINAY, Cédric ,  STEIGERWALD, Robin ,  CHAPLIN, Paul

    IPC分类号： A61K39/155 ,  C12Q1/68

    摘要： Provided herein are recombinant modified vaccinia virus Ankara (MVA) strains as improved vaccines against infection with Respiratory Syncytial Virus (RSV virus) and to related products, methods and uses. Specifically, provided herein are genetically engineered recombinant MVA vectors comprising at least one nucleotide sequence encoding an antigenic determinant of an RSV membrane glycoprotein and at least one nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein. Also provided herein are products, methods and uses thereof, e.g., suitable to affect an immune response in a subject, or suitable to diagnose an RSV infection, as well as to determine whether a subject is at risk of recurrent RSV infection.

    PRODUCTION OF IFN-LAMBDA BY CONVENTIONAL DENDRITIC CELLS AND USES THEREOF
    97.
    发明授权
    PRODUCTION OF IFN-LAMBDA BY CONVENTIONAL DENDRITIC CELLS AND USES THEREOF 有权
    通过常规树突状细胞的IFN-拉姆达的制备，及其用途

    公开(公告)号：EP2513311B1

    公开(公告)日：2017-04-12

    申请号：EP10795952.0

    申请日：2010-12-17

    申请人： Bavarian Nordic A/S

    发明人： HOCHREIN, Hubertus

    IPC分类号： C12N15/117 ,  A61P37/04 ,  A61K35/15

    CPC分类号： C12N15/117 ,  A61K35/15 ,  C12N2310/17

    摘要： In the present invention, CD8+ conventional dendritic cells (CD8+ cDCs) and equivalents thereof (eCD8+ cDCs) in mouse and human have been established as major source of IFN-lambda (IFN-λ) in response to double-stranded (ds) nucleic acids. The invention relates to therapeutic applications of ds nucleic acids or analogs thereof targeting CD8+ and/or eCD8+ cDCs in the prevention and/or treatment of infectious diseases, preferably viral infections, or cancer. Furthermore, the invention relates to an in vitro method for producing IFN-λ and/or generating or obtaining a population of IFN-λ producing CD8+ or eCD8+ cDCs as well as in vitro method for detecting or screening for CD8+ and/or eCD8+ cDCs. In addition, the invention relates to a Flt3-ligand or a M-CSF receptor ligand for use in increasing the level of CD8+ and/or eCD8+ cDCs in a subject suffering from an infectious disease or cancer.

    NOVEL INTERFERON-ALPHA-PRODUCING BONE MARROW DENDRITIC CELLS
    99.
    发明授权
    NOVEL INTERFERON-ALPHA-PRODUCING BONE MARROW DENDRITIC CELLS 有权
    中性干扰素ALPHA PRODUZIERENDE DENTRITISCHE RETIKULUMZELLEN VON KNOCHENMARK

    公开(公告)号：EP2575867B1

    公开(公告)日：2017-03-22

    申请号：EP11723884.0

    申请日：2011-06-03

    申请人： Bavarian Nordic A/S

    发明人： O'KEEFFE, Meredith ,  HOCHREIN, Hubertus

    IPC分类号： C12N5/0784 ,  A61K39/00

    CPC分类号： A61K39/00 ,  A61K2039/5154 ,  A61K2039/5158 ,  C12N5/0639

    摘要： A novel dendritic cell type has been identified within bone marrow, termed myelos interferon dendritic cells (miDC). These novel cells possess the high IFN-alpha producing activity of pDC, but they also display a wide TLR responsiveness along with T-cell stimulation capacities that more closely resemble the conventional DC populations. Moreover, these cells appear less prone to apoptosis upon activation stimuli, including viruses. These cells constitute a novel bone marrow innate immune cell type, ideally geared to linking innate and adaptive immune responses via their potent IFN-alpha production and high cell stimulatory capacity.

    摘要翻译： 已经在骨髓中鉴定了一种称为骨髓干细胞树突状细胞（miDC）的新型树突细胞类型。 这些新型细胞具有pDC高的IFN-α产生活性，但是它们也显示出更广泛的TLR反应性以及更接近常规DC群体的T细胞刺激能力。 此外，这些细胞在激活刺激（包括病毒）时似乎不太容易凋亡。 这些细胞构成了一种新型的骨髓先天免疫细胞类型，理想地用于通过其有效的IFN-α产生和高细胞刺激能力连接先天和适应性免疫应答。